Should I Buy QURE? QURE 2026 Analysis

Should You Buy Uniqure NV (QURE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

23.660

1 Day change

2.76%

52 Week Range

71.500

Analysis Updated At

2026/01/26

Uniqure NV (QURE) is not a good buy for a beginner investor with a long-term strategy at this moment. The stock is facing significant regulatory challenges, reflected in a sharp drop in price and negative sentiment. While the company has shown revenue growth, its financials remain weak with substantial net losses. The technical indicators and options data do not suggest a strong entry point. Additionally, the lack of positive catalysts and uncertainty around its drug approval timeline make it a risky investment for a beginner.

Technical Analysis

The technical indicators are mixed but lean bearish. The MACD is positive and expanding, suggesting some upward momentum. However, the RSI is neutral, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 24.271, with key resistance at 27.182 and support at 21.36.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a slightly bullish sentiment in the options market. However, the implied volatility is high (143.83), suggesting significant uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

Revenue increased by 61.83% YoY in Q3 2025, and gross margin improved to 89.25%, indicating operational efficiency.

Neutral/Negative Catalysts

The FDA's rejection of the BLA submission for AMT-130 has created significant uncertainty, leading to a 57% stock price drop. Multiple law firms are investigating the company for potential securities law violations, further damaging investor confidence. Analysts have significantly lowered price targets, and the regulatory path forward remains unclear.

Financial Performance

In Q3 2025, revenue increased by 61.83% YoY to $3,701,000. However, the company reported a net loss of $80,529,000, an 81.46% increase in losses YoY. EPS improved to -1.38, up 51.65% YoY, but remains negative, reflecting ongoing financial struggles.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have lowered price targets significantly, with the highest recent target at $70 (down from $110) and the lowest at $33. Ratings range from Buy to Neutral, with increasing caution due to regulatory challenges and uncertainty surrounding AMT-130.

10 Analyst Rating

Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 49.88 USD with a low forecast of 33 USD and a high forecast of 70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 23.020

Low

Averages

49.88

High

Current: 23.020

Low

Averages

49.88

High

Barclays

Equal Weight

initiated

$31

AI Analysis

2026-01-27

New

Reason

Barclays

Price Target

$31

AI Analysis

2026-01-27

New

initiated

Equal Weight

Reason

Barclays initiated coverage of uniQure with an Equal Weight rating and $31 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

Stifel

Buy

downgrade

$50 -> $40

2025-12-11

Reason

Stifel

Price Target

$50 -> $40

2025-12-11

downgrade

Buy

Reason

Stifel lowered the firm's price target on uniQure to $40 from $50 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QURE

Unlock Now

QURE Should I Buy

QURE Should I Buy

Should You Buy Uniqure NV (QURE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch